You are here: Industry Insights > ovarian cancer

News List

TESARO, Roche to evaluate triplet therapy for ovarian cancer biospectrumasia
June 07, 2018
TESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform.
EU filing for Clovis’ Rubraca in ovarian cancer maintenance setting pharmatimes
June 06, 2018
Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation worldpharmanews
June 05, 2018
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
Ovarian cancer rates set to rise by 55% pharmafile
May 02, 2018
Ahead of World Ovarian Cancer Day on 8 May, new figures have been released suggesting that rates of this type of cancer are set to greatly increase globally by nearly 55% over the next 20 years.
Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer biospace
April 17, 2018
Syros Pharmaceuticals today announced new preclinical data showing that SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 trial in patients with advanced solid tumors, demonstrated potent anti-tumor activit
ImmunoGen Stock Climbs on Positive Ovarian Cancer Data biospace
March 27, 2018
ImmunoGen has published positive efficacy and tolerability data for its mirwuxuxima soravtansine combined with Merck's Keytruda in the FORWARD II trial in platinum-resistant epithelial ovarian cancer (EOC).
EU approves post-chemo option for patients with ovarian cancer pharmatimes
November 23, 2017
European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
CWCF introduces app for ovarian cancer patients biospectrumasia
September 21, 2017
The app is named after the CA-125 protein, which is produced by ovarian cancer cells and shed into the bloodstream where it can be detected.
LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer americanpharmaceuticalreview
August 21, 2017
AstraZeneca and Merck announced that the U.S. Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, LYNPARZA (olaparib), as follows:
New Findings in Ovarian Cancer Treatment: Another TCM Atractylodes Macrocephala Promoting the Nation en-cphi.cn
July 28, 2017
As one of the most common causes of death among cancers of females, the ovarian cancer has a case fatality rate ranking first in gynecologic malignant tumors.

Previous page 1 2 3 4 5 6 7 8 Next page